Brokers Set Expectations for vTv Therapeutics Inc.’s FY2022 Earnings (NASDAQ:VTVT)

vTv Therapeutics Inc. (NASDAQ:VTVTGet Rating) – Research analysts at Cantor Fitzgerald decreased their FY2022 earnings per share estimates for shares of vTv Therapeutics in a research report issued on Tuesday, November 22nd. Cantor Fitzgerald analyst C. Duncan now expects that the biotechnology company will earn ($0.27) per share for the year, down from their previous estimate of ($0.24). The consensus estimate for vTv Therapeutics’ current full-year earnings is ($0.26) per share. Cantor Fitzgerald also issued estimates for vTv Therapeutics’ FY2023 earnings at ($0.28) EPS.

VTVT has been the subject of a number of other reports. Northland Securities increased their price objective on shares of vTv Therapeutics from $1.50 to $2.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 17th. StockNews.com started coverage on shares of vTv Therapeutics in a report on Thursday. They issued a “hold” rating on the stock.

vTv Therapeutics Trading Up 5.3 %

Shares of NASDAQ VTVT opened at $0.79 on Thursday. The firm has a market cap of $82.62 million, a PE ratio of -2.63 and a beta of -1.26. vTv Therapeutics has a 1-year low of $0.38 and a 1-year high of $1.40. The company has a fifty day moving average price of $0.90 and a 200 day moving average price of $0.85.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds have recently modified their holdings of the business. State Street Corp lifted its holdings in vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 150,228 shares during the period. Millennium Management LLC boosted its holdings in vTv Therapeutics by 12.0% during the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 14,845 shares during the last quarter. Prudential Financial Inc. purchased a new position in vTv Therapeutics during the second quarter worth about $30,000. Finally, Simon Quick Advisors LLC purchased a new position in vTv Therapeutics during the second quarter worth about $36,000. Institutional investors and hedge funds own 7.35% of the company’s stock.

About vTv Therapeutics

(Get Rating)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

See Also

Earnings History and Estimates for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.